Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Eom Pharmaceuticals Inc. currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This active matter is assigned to 1 distinct examiner working within 1 distinct art unit. The concentration of the portfolio suggests a specific focus for current prosecution efforts at the patent office. Because the company is only dealing with this active matter, the administrative burden is relatively low compared to larger portfolios.
The busiest examiner for the company is GU, QINHUA, who is responsible for 1 pending office action. Since this count represents the entirety of the company's pending workload, the prosecution strategy is currently tied to the findings and preferences of this individual. Practitioners should monitor this interaction closely to gauge the immediate trajectory of the company's intellectual property. Success in this matter will depend on addressing the specific technical requirements of the 1 distinct art unit.
The 1 pending office action in the Biotechnology & Pharmaceuticals sector indicates that the company's legal resources are focused on a single point of examination. This allows for a concentrated effort in responding to the examiner's requirements. Understanding the historical allowance rates of GU, QINHUA may provide additional context for the expected timeline of the current prosecution phase.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GU, QINHUA | 1 | 76.2% | +27.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18032986 | EOM613 FOR TREATMENT OF COVID-19 | GU, QINHUA | — |
| Art Unit | Apps |
|---|---|
| 1633 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18032986 | EOM613 FOR TREATMENT OF COVID-19 | GU, QINHUA | 1633 | §103 | Final Rejection | — | Pending | Apr 20, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialEom Pharmaceuticals Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Qinhua Gu has the most, with 1 of Eom Pharmaceuticals Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
